Clinical Trial Update: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma [Phase 3]

View source ↗

Summary

This Phase 3 clinical trial compares belantamab mafodotin plus pomalidomide and dexamethasone against bortezomib plus pomalidomide and dexamethasone in relapsed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Blenrep (belantamab mafodotin)
• Decadron (Dexamethasone)
• Pomalyst (pomalidomide)
• Velcade (bortezomib)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Multiple Myeloma | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-03-18